Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Dec 2022
Historique:
received: 09 11 2022
revised: 15 12 2022
accepted: 19 12 2022
entrez: 8 1 2023
pubmed: 9 1 2023
medline: 11 1 2023
Statut: epublish

Résumé

Distant spreading of tumor cells to the central nervous system in non-small cell lung cancer (NSCLC) occurs frequently and poses major clinical issues due to limited treatment options. RNAs displaying differential expression in brain metastasis versus primary NSCLC may explain distant tumor growth and may potentially be used as therapeutic targets. In this study, we conducted systematic microRNA expression profiling from tissue biopsies of primary NSCLC and brain metastases from 25 patients. RNA analysis was performed using the nCounter Human v3 miRNA Expression Assay, NanoString technologies, followed by differential expression analysis and in silico target gene pathway analysis. We uncovered a panel of 11 microRNAs with differential expression and excellent diagnostic performance in brain metastasis versus primary NSCLC. Five microRNAs were upregulated in brain metastasis (miR-129-2-3p, miR-124-3p, miR-219a-2-3p, miR-219a-5p, and miR-9-5p) and six microRNAs were downregulated in brain metastasis (miR-142-3p, miR-150-5p, miR-199b-5p, miR-199a-3p, miR-199b-5p, and miR-199a-5p). The differentially expressed microRNAs were predicted to converge on distinct target gene networks originating from five to twelve core target genes. In conclusion, we uncovered a unique microRNA profile linked to two target gene networks. Our results highlight the potential of specific microRNAs as biomarkers for brain metastasis in NSCLC and indicate plausible mechanistic connections.

Identifiants

pubmed: 36613642
pii: ijms24010193
doi: 10.3390/ijms24010193
pmc: PMC9820685
pii:
doi:

Substances chimiques

MicroRNAs 0
Mirn129 microRNA, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Nature. 2007 Jun 14;447(7146):799-816
pubmed: 17571346
Onco Targets Ther. 2019 Nov 05;12:9165-9175
pubmed: 31807001
Cancers (Basel). 2019 Apr 30;11(5):
pubmed: 31052206
Hum Cell. 2019 Oct;32(4):437-446
pubmed: 31168689
Cell Physiol Biochem. 2017;43(6):2505-2515
pubmed: 29131028
Tumour Biol. 2014 Jun;35(6):5287-93
pubmed: 24532468
Curr Cancer Drug Targets. 2021;21(8):702-712
pubmed: 33858314
J Neurooncol. 2017 Nov;135(2):413-418
pubmed: 28780743
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Mol Carcinog. 2020 May;59(5):557-568
pubmed: 32159887
Am J Cancer Res. 2019 Mar 01;9(3):585-596
pubmed: 30949412
J Thorac Oncol. 2019 Jul;14(7):1244-1254
pubmed: 30780002
J Clin Oncol. 2016 Aug 20;34(24):2814-9
pubmed: 27298405
Mol Med Rep. 2017 Sep;16(3):3557-3564
pubmed: 28714014
Int J Clin Exp Pathol. 2015 Jan 01;8(1):842-6
pubmed: 25755784
Eur J Cancer. 2020 Jun;132:24-34
pubmed: 32325417
Gene. 2017 Jul 15;620:15-22
pubmed: 28363780
Onco Targets Ther. 2021 Aug 04;14:4335-4343
pubmed: 34376998
Sci Rep. 2016 Dec 15;6:39001
pubmed: 27976702
Biomedicines. 2021 Dec 11;9(12):
pubmed: 34944699
Eur J Cancer. 2014 Mar;50(5):1013-24
pubmed: 24456795
Mol Ther Nucleic Acids. 2019 Jun 7;16:675-685
pubmed: 31121479
Int J Mol Sci. 2021 Jul 17;22(14):
pubmed: 34299277
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211048592
pubmed: 34723712
Oncology. 2003;64(1):28-35
pubmed: 12457029
Lancet Oncol. 2021 Feb;22(2):198-211
pubmed: 33476593
FEBS Open Bio. 2018 Aug 30;8(9):1544-1552
pubmed: 30186753
Cancers (Basel). 2020 Jul 06;12(7):
pubmed: 32640547
Cancer Manag Res. 2020 Nov 13;12:11597-11609
pubmed: 33223850
Pathol Biol (Paris). 1997 Dec;45(10):852-63
pubmed: 9769949
Int J Mol Sci. 2022 Jul 31;23(15):
pubmed: 35955652
Cancer Res. 2007 Apr 15;67(8):3496-9
pubmed: 17440054
Medicine (Baltimore). 2022 Sep 9;101(36):e30393
pubmed: 36086747
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Mol Sci. 2014 Jun 11;15(6):10508-26
pubmed: 24921708
Nat Cell Biol. 2017 Jun;19(6):711-723
pubmed: 28530657
Cancer Invest. 2002;20(3):293-302
pubmed: 12025223
Pathol Res Pract. 2020 Nov;216(11):153145
pubmed: 32827803
Oncol Rep. 2018 Aug;40(2):943-951
pubmed: 29901178
J Thorac Oncol. 2018 Nov;13(11):1717-1726
pubmed: 29981925
Int J Oncol. 2018 Mar;52(3):913-924
pubmed: 29286099
Science. 2017 Aug 18;357(6352):
pubmed: 28818916
PLoS Genet. 2019 Feb 1;15(2):e1007888
pubmed: 30707694
Biomed Pharmacother. 2017 Dec;96:1170-1178
pubmed: 29239816
Cancer Discov. 2014 Apr;4(4):405-14
pubmed: 24658082
Cancer. 2012 Sep 15;118(18):4502-11
pubmed: 22282022
Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7430-7437
pubmed: 31539130
Nature. 2021 Dec;600(7888):319-323
pubmed: 34819663
J Cancer. 2019 Jun 2;10(11):2472-2479
pubmed: 31258753
Pathol Res Pract. 2022 Sep;237:154053
pubmed: 35926432
Acta Pharm Sin B. 2021 Dec;11(12):3950-3965
pubmed: 35024318
Int J Clin Exp Pathol. 2015 Sep 01;8(9):10800-7
pubmed: 26617792
Thorac Cancer. 2022 Apr;13(7):956-964
pubmed: 35146917
Curr Protoc Bioinformatics. 2017 Jun 27;57:7.15.1-7.15.30
pubmed: 28654712
Front Cell Dev Biol. 2021 Feb 18;8:620615
pubmed: 33681184

Auteurs

Georgios Tsakonas (G)

Thoracic Oncology Center, Karolinska University Hospital, 17176 Stockholm, Sweden.
Department of Oncology and Pathology, Karolinska Institutet, 17164 Stockholm, Sweden.

Andreas Koulouris (A)

Thoracic Oncology Center, Karolinska University Hospital, 17176 Stockholm, Sweden.

Dominika Kazmierczak (D)

Department of Oncology and Pathology, Karolinska Institutet, 17164 Stockholm, Sweden.

Johan Botling (J)

Department of Immunology, Genetics and Pathology, Uppsala University, 75105 Uppsala, Sweden.

Cristian Ortiz-Villalon (C)

Department of Oncology and Pathology, Karolinska Institutet, 17164 Stockholm, Sweden.

Helena Nord (H)

Department of Immunology, Genetics and Pathology and Science for Life Laboratory, Uppsala University, 75105 Uppsala, Sweden.

Magnus Lindskog (M)

Department of Immunology, Genetics and Pathology, Uppsala University, 75105 Uppsala, Sweden.
Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, 17176 Stockholm, Sweden.

Martin Sandelin (M)

Department of Medical Sciences, Department of Oncology, University Hospital, Uppsala University, 75185 Uppsala, Sweden.

Patrick Micke (P)

Department of Immunology, Genetics and Pathology, Uppsala University, 75105 Uppsala, Sweden.

Per Hydbring (P)

Department of Oncology and Pathology, Karolinska Institutet, 17164 Stockholm, Sweden.

Simon Ekman (S)

Thoracic Oncology Center, Karolinska University Hospital, 17176 Stockholm, Sweden.
Department of Oncology and Pathology, Karolinska Institutet, 17164 Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH